Salmeterol/fluticasone proprionate - Teva Pharmaceutical Industries

Drug Profile

Salmeterol/fluticasone proprionate - Teva Pharmaceutical Industries

Alternative Names: Aerivio Spiromax®; AirDuoTM RespiClick; Fluticasone propionate/salmeterol - Teva; Fluticasone propionate/salmeterol MDI; Fluticasone propionate/salmeterol MDPI; Fluticasone/salmeterol Spiromax® inhalation powder; FS Spiromax; Salmeterol xinafoate/fluticasone propionate - Teva; Salmeterol/fluticasone propionate RespiClick®; Salmeterol/fluticasone propionate Spiromax®

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma
  • Registered Chronic obstructive pulmonary disease

Most Recent Events

  • 20 Apr 2017 Launched for Asthma (In adolescents, In adults) in USA (Inhalation) - First global approval
  • 06 Mar 2017 Updated efficacy data from a phase III trial in Asthma presented at the 2017 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2017)
  • 30 Jan 2017 Registered for Asthma (In adolescents, In adults) in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top